Need professional-grade analysis? Visit stockanalysis.com
$6.07B
N/A
N/A
N/A
Terns Pharmaceuticals Inc (TERN) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $52.65, down 0.08% from the previous close.
Over the past year, TERN has traded between a low of $2.78 and a high of $53.17. The stock has gained 1780.4% over this period. It is currently 1793.9% above its 52-week low.
Terns Pharmaceuticals Inc has a market capitalization of $6.07B.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Side-by-side comparison against top Healthcare peers.